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Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by intense 
inflammation and multiple organ damage (1). There is much evidence for genetic susceptibility 
to SLE and several candidate genes including that encoding the angiotensin-converting enzyme 
(ACE) have been identified (2). Biologically, ACE elevates the levels of angiotensin II, a 
vasoactive peptide, growth factor and potent pro-inflammatory modulator, which contributes to 
tissue remodelling (3, 4). The ACE gene contains a 287-base pair repeat insertion/deletion (I/D) 
polymorphism within intron 16 (5), and studies have shown that D/D homozygotes have an 
approximate two-fold higher level of tissue and plasma ACE as compared with I/I homozygotes 
(6). Although the D/D genotype and the concomitant increase in serum ACE and angiotensin II 
levels could contribute to the pathogenesis of SLE (3, 4), there are conflicting data with regard 
to the association of the ACE D/D genotype and susceptibility to the disease (7). The aim of the 
current study was to investigate ACE I/D gene polymorphisms and serum ACE levels in Indian 
SLE patients, and to determine any correlations to the clinical features of SLE. 
One hundred and nine SLE patients (6 male, 103 female; mean age 27.8 ± 9.7 years with 
range 12-60 years) were recruited to this single-centre prospective observational study at the 
King Edward Memorial Hospital, Mumbai, Maharashtra, India, between January 2010 and 
January 2012. The clinical details of the SLE patient group are given in Supplementary Table 1. 
SLE was diagnosed according to the revised and updated criteria of the American Rheumatism 
Association for the classification of SLE (8, 9). Of the SLE patients, 39 were untreated at the 
point of inclusion in the study, and 70 were receiving corticosteroid treatment. A total of 100 
unrelated healthy individuals without SLE or other autoimmune disease, or a history thereof, and 
matched for ethnicity, sex and age, were also included in the study as controls. Approval for the 
study was given by the institutional ethics committee, and written informed consent was 
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obtained from all participants. The study was conducted in accordance with the Declaration of 
Helsinki Principles. 
In a case-control study, the ACE I/D genotypes and serum ACE levels were determined 
for 109 SLE patients and 100 age and sex-matched controls using PCR amplification and an 
ELISA, respectively (Supplementary Material). The observed genotype frequencies of the 
controls (Table 1) did not differ significantly from the frequencies predicted by the Hardy-
Weinberg equilibrium (P = 0.11). There was a strong statistical trend for an increase of the D/D 
and I/D genotypes in SLE, while there was a statistically significant increase in the D allele (Table 
1). Serum ACE levels were significantly higher in the SLE patient group compared with controls 
(Table 1). In both SLE patients and controls, the D/D genotype correlated with the highest levels 
of serum ACE (Figure 1). Serum ACE levels in SLE patients were also increased significantly 
when compared with controls of the same ACE I/D genotype (Figure 1). There was no significant 
difference in the prevalence of ACE I/D genotypes or alleles or in the levels of serum ACE in 
relation to SLE activity, as measured by SLE disease activity indices (SLEDAI), or to the 
presence of vasculopathy or lupus nephritis (Table 1). SLEDAI scores did not differ significantly 
in relation to the D/D, D/I and I/I ACE genotypes: the median, 25th and 75th percentiles, and range 
were, respectively, 14, 11, 22, 6-51; 13, 10, 18, 3-34; and 10, 15, 21, 8-27 (P = 0.20, Kruskal-
Wallis test), and no significant correlation was found between SLEDAI scores and serum ACE 
levels (r = -0.09 with 95% confidence intervals -0.28-0.11; P = 0.37, Spearman’s rank correlation 
test).  
Here, we provide evidence of an association between SLE and the D allele of the ACE I/D 
genotype, and between SLE and elevated levels of serum ACE in an Indian population. As 
reported before (6), the ACE D/D genotype was associated with significantly higher levels of 
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serum ACE. This has been suggested to result from either strong linkage disequilibrium of the I/D 
polymorphism with regulatory elements of ACE which are responsible for the variation in enzyme 
levels, or from alterations in mRNA stability or precursor mRNA splicing (6). Although how 
increased levels of serum ACE can result in SLE manifestations remains unestablished, elevated 
levels have been associated with an increased generation of reactive oxygen species which can 
lead to oxidative stress and subsequent tissue damage (10). 
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Figure Legend 
 
Figure 1: Serum ACE levels in relation to ACE genotypes in SLE patients and controls. 
Serum ACE levels (pg/ml) are shown as the medians, 25th and 75th percentiles, and ranges 
for SLE patient and control groups. Serum ACE levels in SLE patients and controls with the 
ACE D/D genotype were significantly increased compared to those with other ACE I/D 
genotypes (P values were < 0.0001, Kruskal-Wallis test). Serum ACE levels of the SLE 
patients were significantly increased when compared with controls of the same ACE I/D 
genotype (P values were < 0.0001, Kruskal-Wallis test).  
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Table 1. Distribution and comparison of ACE I/D genotypes and alleles and of serum ACE levels in SLE patients and 
controls.  
 
NA, not applicable. 
SLEDAI, SLE disease activity index. 
P values < 0.05 considered significant. 
a
Chi-square test with Yate’s correction for contingency tables comparing SLE patients with controls or comparing SLE patient sub-groups. The 
Bonferroni-adjusted P values were not significant in multiple comparisons of lupus nephritis and vasculopathy in relation to I/D genotypes. 
b
Mann-Whitney test comparing SLE patients with controls. 
c
Kruskal-Wallis test comparing SLE patient sub-groups. 
d
Class I, minimal mesangial lupus nephritis; class II, mesangial proliferative lupus nephritis; class III, focal lupus nephritis; class IV, diffuse lupus 
nephritis; class V, membranous lupus nephritis; and class VI, advanced sclerosing lupus nephritis 
 
Patient or control group 
 
 
Number 
of 
subjects 
 
 
Number of alleles 
in the group (%) 
 
 
P value
a
 
 
Odds ratio  
(95% 
confidence 
interval) 
 
P value
a
 
 
Number of subjects with 
genotype (%) 
 
 
P value
a
 
 
P value
a
 
 
Serum ACE 
levels in 
pg/ml 
(median) 
and range 
 
P value
b
 
 
P value 
 
D 
 
I 
 
D/D 
 
I/D 
 
I/I 
Healthy controls 100 101 (51) 99 (49) NA NA NA 22 (22) 57 (57) 21 (21) NA NA 2000; 1200-
1400 
NA NA 
SLE patients 109 133 (61) 85 (39) 0.04 1.53 (1.04-2.26) NA 36 (33) 61 (56) 12 (11) 0.06 NA 3800; 2400-
6200 
< 0.0001 NA 
SLEDAI 1-8 16 16 (50) 16 (50) 0.96 0.98 (0.46-2.07) 0.30 2 (13) 12 (75) 2 (16) 0.40 0.33 3800; 2800-
5600 
< 0.0001 0.45
c
 
SLEDAI 9-18 63 77 (61) 49 (39) 0.08 1.54 (0.98-2.42) 21 (33) 35 (56) 7 (11) 0.13 4000; 2500-
6200 
< 0.0001 
SLEDAI > 18 30 40 (67) 20 (33) 0.04 1.96 (1.07-3.59) 13 (43) 14 (47) 3 (10) 0.05 3645; 2400-
6200 
< 0.0001 
Lupus nephritis 34 42 (62) 26 (38) 0.14 1.58 (0.90-2.78) 0.99 13 (38) 16 (47) 5 (15) 0.17 0.42 3900; 2900-
6200 
< 0.0001 0.55
b
 
No lupus nephritis 75 91 (61) 59 (39) 0.08 1.51 (0.98-2.32) 23 (31) 45 (60) 7 (9) 0.08 3700; 2400-
6200 
< 0.0001 
Class I/ II/III lupus 
nephritis
d
 
10 15 (75) 5 (25) 0.06 0.34 (0.12-0.97) 0.57 6 (60) 3 (30) 1 (10) 0.03 0.87 4550; 3000-
5500 
< 0.0001 0.40
c
 
Class IV lupus nephritis
d
 18 23 (64) 13 (36) 0.19 0.58 (0.28-1.20) 8 (44) 7 (39) 3 (17) 0.13 3950; 3000-
6200 
< 0.0001 
Class V/VI lupus 
nephritis
d
 
6 7 (58) 5 (42) 0.81 0.73 (0.22-2.37) 2 (33) 3 (50) 1 (17) 0.81 3600; 2900-
6000 
0.0006 
Vasculopathy 15 18 (60) 12 (40) 0.44 0.68 (0.31-1.49) 0.90 4 (27) 10 (67) 1 (7) 0.42 0.65 3690; 2400-
5200 
< 0.0001 0.13
b
 
No vasculopathy 94 115 (61) 73 (39) 0.04 0.65 (0.43-0.97) 32 (34) 51 (54) 11 (12) 0.08 3850; 2690-
6200 
< 0.0001 
Page 8 of 15
Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology
For Peer Review
9 
 
 
Page 9 of 15
Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology
For Peer Review
  
 
 
 
47x30mm (300 x 300 DPI)  
 
 
Page 10 of 15
Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology
For Peer Review
1 
 
Supplementary Material 
 
Materials and Methods 
ACE gene I/D polymorphism analysis 
High molecular weight genomic DNA was prepared from EDTA-collected venous blood 
samples (10-20 ml) using a Cyclo-3UHS*HQRPLF'1$,VRODWLRQ.LW(Genetix Biotech 
$VLD1HZ'HOKL,QGLDDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGZDVVWRUHGLQ
Tris-EDTA buffer (pH 8.0) at -20°C. Genomic DNA was subjected to PCR amplification 
XVLQJROLJRQXFOHRWLGHSULPHUV¶-CTGGAGACCACTCCCATCCTTTCT-3c (forward) and 
¶-GATGTGGCCATCACATTCGTCAGAT-¶ UHYHUVH (XURILQV*HQRPLFV%DQJDORUH
India) in order to amplify the I/D polymorphic 287-base pair repetitive sequence 
(rs1799752) in intron 16 of the ACE gene (Reference sequence AF118569, repeat 
region 14094-14381; National Center for Biotechnology Information, Bethesda, MD, 
USA). 
 
PCR amplifications were performed on 100 ng of genomic DNA in 25-Pl reactions 
containing: 0.5 units of TaqI DNA polymerase (Chromos Biotech, Bengaluru, India), 1 
µM of each primer, 0.2 mM of each deoxynucleotide triphosphate (dATP, dCTP, dGTP 
and dTTP) (Chromos Biotech), 1.5 mM magnesium chloride (Chromos Biotech) and 0.2 
volumes of 5x buffer (50 mM Tris-hydrochloride, pH 8.5; 0.05% (w/v) gelatin; 250 mM 
potassium chloride; 0.5% (v/v) Tween 20; and 0.5% (v/v) Nonidet P-40) (Chromos 
Biotech). The PCR amplifications were performed in an Eppendorf Mastercycler® 
gradient thermo cycler (Eppendorf North America, Inc., Hauppauge, NY, USA) under 
the following conditions: initial denaturation at 95°C for 5 min; 30 cycles of amplification 
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at 94°C for 1 min, 58°C for 1 min and 72°C for 1 min; and a final extension at 72°C for 7 
min. 
 
PCR amplification products were analysed in 1.5% (w/v) agarose gels along with pUC 
Mix Marker 8 DNA fragment size markers (Thermo Fisher Scientific Inc., Waltham, MA, 
USA). Following staining with ethidium bromide, gels were visualised under UV light 
and genotyped according to the following pattern: the presence of a single PCR 
amplification product of 480 base pairs represented an I/I homozygous individual, the 
presence of a single PCR amplification product of 193 base pairs represented a D/D 
homozygous individual, and the presence of both PCR amplification products 
represented a I/D heterozygous individual. The accuracy of the genotyping protocol 
was verified by repeating the PCR analysis on 20 randomly selected DNA samples. All 
initial results were verified by this re-analysis. 
 
Enzyme-linked immunosorbent assay for serum ACE level measurement 
Venous blood samples (10-20 ml) were collected from patients and controls, serum 
prepared and stored at -80°C until required. Enzyme-linked immunosorbent assay 
(ELISA) kits for measuring serum ACE levels in patient and control sera were 
purchased from Bio Vendor-Laboratoni Medicina a.s (Brno, Czech Republic) and used 
DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO 6HUD ZHUH DQDO\VHG LQ WULSOLFDWH LQ WZR 
experiments, and ACE levels were reported as pg/ml. Intra- and inter-assay coefficients 
of variation were < 10%. 
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Statistical analyses 
Statistical analysis was carried out using GraphPad InStat 3 software (GraphPad 
Software Inc., La Jolla, CA, USA). The frequencies of the ACE I/D genotypes and 
alleles in SLE patient and control groups were compared using the Chi-square test with 
<DWH¶V FRUUHFWLRQ IRU FRQWLQJHQF\ WDEOHV. Odds ratios with 95% confidence intervals 
were calculated according to a previous method (1). Expected genotype counts were 
calculated according to the Hardy-Weinberg equilibrium (2), and compared with 
observed genotypes in the Chi-square test. Comparison of continuous variables was 
carried out using Mann-Whitney or Kruskal-Wallis tests, as appropriate. Bonferroni-
adjusted P values were calculated for multiple comparisons of variables. 6SHDUPDQ¶V
rank (r) correlation test was used to measure the statistical dependence between two 
variables. In all tests, P values (two-tailed) < 0.05 were regarded as significant. 
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Supplementary Table 1. Clinical details of SLE patients included in the study 
 
 
aDisease activity was assessed using the SLE disease activity index (SLEDAI) (3). 
bHistological findings in renal biopsies were classified according to the International Society 
of Nephrology/Renal Pathology Society (ISN/RPS) 2003 criteria (4). 
  
 
Clinical feature 
 
 
Number (%) of SLE patients or detail 
of SLE patient group 
 
Mean age at SLE onset ± SD 25.7 ± 9.2 years (range 11-67 years) 
Mean SLE duration ± SD 2.1 ± 2.9 years (range < 1-20 years) 
SLE activitya:  
Mean SLEDAI  ± SD 
SLEDAI 1-8  
SLEDAI 9-18 
SLEDAI > 18  
 
15.3 ± 7.6 years (range 3-51 years)  
16 (14.7) 
63 (57.8) 
30 (27.5) 
Clinical manifestations: 
Lupus nephritis 
Arthritis 
Alopecia 
Myositis 
Urinary casts 
Hematuria 
Proteinuria 
5D\QDXG¶VSKHQRPHQRQ 
Cutaneous vasculitis 
Photosensitivity 
Mucosal ulcers 
Malar rash 
Leukopenia 
Thrombopenia 
Pleurisy 
Fever 
Seizures 
Psychosis 
Organic brain syndrome; cranial nerve disorder; lupus 
headache; new onset of cerebrovascular accident(s) 
excluding arteriosclerosis 
New skin rash 
 
34 (31.2) 
68 (62.4) 
76 (69.7) 
11 (10.1) 
27 (24.8) 
30 (27.5) 
32 (29.4) 
11 (10.1) 
6 (5.5) 
40 (36.7) 
58 (53.2) 
49 (45.0) 
7 (6.4) 
8 (7.3) 
13 (11.9) 
50 (45.9) 
5 (4.6) 
5 (4.6) 
3 (2.8) 
 
 
6 (5.5) 
Serological analysis: 
Anti-nuclear autoantibodies 
Anti-DNA autoantibodies 
 
109 (100) 
100 (91.7) 
Renal pathologyb: 
Class I, Minimal mesangial lupus nephritis  
Class II, Mesangial proliferative lupus nephritis  
Class III, Focal lupus nephritis 
Class IV, Diffuse lupus nephritis  
Class V, Membranous lupus nephritis  
Class VI, Advanced sclerosing lupus nephritis  
 
2/34 (5.9) 
4/34 (11.8) 
4/34 (11.8) 
18/34 (52.9) 
4/34 (11.8) 
2/34 (5.9) 
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